Portola Pharmaceuticals Announces Presentation Of Preclinical Data On Andexanet Alfa (PRT44545), Factor Xa Inhibitor Antidote, At 2013 European Society Of Cardiology Congress

Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) today announced that it will present preclinical data on its investigational Factor Xa inhibitor antidote andexanet alfa (PRT4445*) in a moderated poster session at the upcoming 2013 European Society of Cardiology (ESC) Congress, which is taking place in Amsterdam from August 31-September 4.

“These data from a preclinical animal model are noteworthy because they demonstrate that the reversal of Factor Xa anticoagulant activity by andexanet alfa has the potential to reduce blood loss in anticoagulated patients experiencing an active bleed, an important point of differentiation with this compound,” said John T. Curnutte, M.D., Ph. D., executive vice president of research and development for Portola. “We have already established in a Phase 2 clinical study that andexanet alfa can reverse the anticoagulant activity of the Factor Xa inhibitor Eliquis ® (apixaban), and, as part of an accelerated development plan, we expect to initiate a pivotal study in 2014 to further assess the effects of andexanet alfa on bleeding.”

Details of the moderated poster presentation follow:

Abstract title: PRT064445 (Andexanet Alfa) Reverses Rivaroxaban Induced Anticoagulation in a Rabbit Liver Laceration “Treatment” Model

Session: Antithrombotic Agents

Presentation date/time: August 31, 2013, 16:22 p.m. CEST

Location: Moderated Posters -- Village 9

Moderator: Stanley Hollenbach, J.D., vice president, pharmacology, Portola Pharmaceuticals

The andexanet alfa abstract is now publically available at http://spo.escardio.org/.

About Andexanet Alfa

Andexanet alfa (proposed INN) is a novel recombinant, modified Factor Xa molecule designed to reverse the anticoagulant activity in patients treated with a Factor Xa inhibitor who suffer an uncontrolled bleeding episode or need to undergo emergency surgery. Andexanet alfa is similar to native Factor Xa, but has been modified to restrict its biological activity to the reversal of the anticoagulant effects of Factor Xa inhibitors. Andexanet alfa acts as a Factor Xa decoy that binds and sequestors direct Factor Xa inhibitors in the blood. Once bound to andexanet alfa, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa. The native Factor Xa is then available to participate in the coagulation process and restore hemostasis.

If you liked this article you might like

Portola Shares Lower After Pricing Stock Offering - Biotech Movers

Norwegian Cruise Line, iRobot, Bank of America: 'Mad Money' Lightning Round

What's Getting In This Rally's Way: Cramer's 'Mad Money' Recap (Thurs 8/24/17)

These Biotech Stocks are BOOMING

Cramer: Don't Risk It All on a Small Biotech Unless You're Willing to Lose It All